Skip to content
Extreme Investor Network
  • Contact Us
  • Privacy Policy

Nasal

FDA Grants Approval for Johnson & Johnson’s Spravato Nasal Spray for Depression Treatment.

January 21, 2025
FDA approves Johnson & Johnson nasal spray Spravato for depression

The Revolutionary Step in Mental Health Treatment: Johnson & Johnson’s Spravato Approved for Standalone Use In a groundbreaking move for the treatment of major depressive disorders, the Food and Drug Administration (FDA) has granted approval … Read more

Categories Business News Tags Approval, depression, FDA, grants, Johnson, Johnsons, Nasal, Spravato, Spray, Treatment

Categories

Recent Posts

  • E.l.f. Beauty CEO Discusses January’s Weaker Sales TrendsFebruary 6, 2025
  • Tokenization Poised to Revolutionize Asset Management in the U.S.February 6, 2025
  • Predictions for Enterprise Products Partners L.P. (EPD) Stock PerformanceFebruary 6, 2025
  • Crude Oil Price Outlook: Strong Bearish Momentum Develops During Market CorrectionFebruary 6, 2025
  • Big Tech and the Magnificent 7: Is It Time to Cut Back on Your Investments?February 6, 2025
  • Denver Broncos President Damani Leech Commends NFL’s Commitment to DiversityFebruary 6, 2025
  • Certain Census Bureau Data Now Unavailable to the PublicFebruary 6, 2025
  • Investors Should Consider ‘Countertrend’ Stocks at This Moment: Katie StocktonFebruary 6, 2025
  • Experts Highlight Significant Refund Opportunities from Tax Credits for Low-Income EarnersFebruary 6, 2025
  • Market Update – February 6, 2025February 6, 2025

Archives

© 2025 Extreme Investor Network

Usermaven | Website analytics and product insights